Analyst Insights

Read our Analysts’ insights and expert opinions on the latest healthcare technology industry developments and market trends. Signify Research provides both free insights and premium insights which are only available to subscribers of "Signify Premium Insights".
Click on the premium insights link below to filter for just the premium content.

Signify Premium Insight: Perspectum’s Persuasive Value Proposition

Signify Premium Insights Subscription Required

February 2nd 2023 – Perspectum has recently secured $36m in Series C funding. It is a figure that, compared to its peers, is surprisingly low, particularly given Perspectum’s credentials. Is there a reason for this financial modesty?

Signify Premium Insight: MDR Postponement: Impact on EHR and Drug CDS Product Roadmap

Signify Premium Insights Subscription Required

2nd February 2023 – An EU Commission proposal to push back the deadline for re-certifying medical devices from May 2024 to May 2028 will dampen demand for more sophisticated drug Clinical Decision Support (CDS) products.

The Quickening Pulse of the Ambulatory Diagnostic Cardiology Market

1st February 2023 – The Global Ambulatory Diagnostic Cardiology Market is evolving at a rapid pace, driven by technological developments, and shifting models of healthcare service delivery and funding. The overall market will grow from $2.5 billion in 2021, to $3.3 billion by 2026.

Signify Premium Insight: In Contrast to Convention, Guerbet Bets on Intrasense

Signify Premium Insights Subscription Required

January 31st 2023 – Guerbet has upped its focus on AI with an investment in French vendor Intrasense. Not only does this add options for providers looking for an AI platform, it also raises possibilities in AV.

Signify Premium Insight: Verily and the Truth Behind its Restructuring Programme

Signify Premium Insights Subscription Required

31st January 2023 – Fresh from a $1B cash injection from Google last September, life sciences business Verily is embarking on a restructuring exercise to exit unprofitable projects and double down on products and services with high potential.